Your browser doesn't support javascript.
loading
Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
Zhu, Ka-Li; Jiang, Xiao-Lin; Zhan, Bing-Dong; Wang, Xue-Jun; Xia, Xian; Cao, Guo-Ping; Sun, Wen-Kui; Huang, Peng-Xiang; Zhang, Jin-Zhong; Gao, Yu-Ling; Dai, Er-Hei; Gao, Hui-Xia; Ma, Mai-Juan.
Afiliação
  • Zhu KL; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 10071, China; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, China.
  • Jiang XL; Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.
  • Zhan BD; Department of Diseases Control and Prevention, Quzhou Center for Disease Control and Prevention, Quzhou 324000, China.
  • Wang XJ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 10071, China.
  • Xia X; Department of Diseases Control and Prevention, The Seventh Medical Center of Chinese PLA General Hospital, Beijing 100700, China.
  • Cao GP; Department of Diseases Control and Prevention, Quzhou Center for Disease Control and Prevention, Quzhou 324000, China.
  • Sun WK; Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.
  • Huang PX; Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.
  • Zhang JZ; Department of Diseases Control and Prevention, Liaocheng Center for Disease Control and Prevention, Liaocheng 252000, China.
  • Gao YL; Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang 050021, China.
  • Dai EH; Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang 050021, China.
  • Gao HX; Department of Laboratory Medicine, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang 050021, China. Electronic address: swysjb@163.com.
  • Ma MJ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 10071, China; Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, China. Electronic address: mjma@163.com.
Cell Rep ; 42(2): 112075, 2023 02 28.
Article em En | MEDLINE | ID: mdl-36774551
Booster immunizations and breakthrough infections can elicit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant neutralizing activity. However, the durability of the neutralization response is unknown. We characterize the sensitivity of BA.1, BA.2, BA.2.75, BA.4/BA.5, BF.7, BQ.1.1, and XBB against neutralizing antibodies from vaccination, hybrid immunity, and breakthrough infections 4-6 months after vaccination and infection. We show that a two-dose CoronaVac or a third-dose ZF2001 booster elicits limited neutralization against Omicron subvariants 6 months after vaccination. Hybrid immunity as well as Delta, BA.1, and BA.2 breakthrough infections induce long-term persistence of the antibody response, and over 70% of sera neutralize BA.1, BA.2, BA.4/BA.5, and BF.7. However, BQ.1.1 and XBB, followed by BA.2.75, are more resistant to neutralization, with neutralizing titer reductions of ∼9- to 41-fold, ∼16- to 63-fold, and ∼4- to 25-fold, respectively. These data highlight additional vaccination in CoronaVac- or ZF2001-vaccinated individuals and provide insight into the durability of neutralization against Omicron subvariants.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: COVID-19 / Infecções Irruptivas Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: COVID-19 / Infecções Irruptivas Limite: Humans Idioma: En Revista: Cell Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China